| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62465a27d0b2c05d576ea9390ec1c6fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06022b4ec16b8aa3f8a0c87f783b63a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9c9fce31ca8425e918d827fe31acb360 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-11 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0648 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0781
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0786
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
1999-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ad9268dc6a5ddfe9e91f7236a8c31a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba10f55aa4d72156eb5a5eead81f27af |
| publicationDate |
2000-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0015767-A2 |
| titleOfInvention |
Antigen-presenting cells and their use in therapy |
| abstract |
A method for ex vivo treatment of antigen presenting cells, wherein said method consists of in vitro culture of antigen presenting cells under conditions resulting in development of tolerogenic antigen presenting cells, such tolerogenic cells being characterised by: a) reduced induction of T cell activation upon T-cell receptor ligation as can be determined by any of the measurements selected from the group measurement of proliferation, measurement of cytokine production, measurement of cytotoxicity and measurement of expression of activation cell surface markers, b) a dominant tolerogenic effect. Also part of the invention are such tolerogenic antigen-presenting cells and artificial analogues, compositions containing them and their use in immunotherapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017034459-A1 |
| priorityDate |
1998-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |